Genomictree Inc. (KOSDAQ:228760)
South Korea · Delayed Price · Currency is KRW 9,890.00
-80.00 (-0.80%)
Nov 2, 2026, 3:30 PM KST
Genomictree Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,946 | 3,760 | 2,362 | 3,418 | 29,866 | 5,140 |
Revenue Growth | -17.13% | 59.17% | -30.89% | -88.55% | 481.09% | 314.87% |
Gross Profit Gross Profit Growth | -164.4 | 699 | -745.56 | -301.62 | 24,974 | 2,499 |
Operating Income Operating Income Growth | -11,738 | -11,298 | -15,313 | -17,303 | 2,405 | -9,855 |
Net Income Net Income Growth | -9,027 | -8,986 | -10,242 | -8,756 | -6,631 | -11,425 |
Earnings Per Share EPS Growth | -372.87 | -374.27 | -429.00 | -448.80 | -316.00 | -553.38 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Genomic Analysis and Other Business Genomic Analysis and Other Business Growth | 400.21 | 316.82 | 163.41 | 1,596 | 28,088 | 2,839 |
Cancer Molecular Diagnosis Business Cancer Molecular Diagnosis Business Growth | 2,546 | 3,443 | 2,199 | 1,822 | 1,778 | 2,301 |
Total Total Growth | 2,946 | 3,760 | 2,362 | 3,418 | 29,866 | 5,140 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 79,181 | 77,366 | 96,080 | 93,146 | 114,605 | 130,542 |
Total Debt Total Debt Growth | 43.98 | 2,368 | 2,079 | 1,835 | 29,180 | 38,444 |
Net Cash (Debt) Net Cash Growth | 79,137 | 74,998 | 94,001 | 91,312 | 85,425 | 92,098 |
Net Cash Growth | -5.79% | -20.21% | 2.94% | 6.89% | -7.25% | 0.57% |
Net Cash Per Share Net Cash Per Share Growth | 3267.30 | 3123.84 | 3936.62 | 3444.88 | 4069.68 | 4461.03 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -10,547 | -10,193 | -13,633 | -10,881 | 4,286 | -7,631 |
Capital Expenditures CapEx Growth | -1,860 | -2,726 | -2,484 | -239.08 | -1,762 | -10,963 |
Free Cash Flow Free Cash Flow Growth | -12,407 | -12,919 | -16,118 | -11,120 | 2,523 | -18,593 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -5.58% | 18.59% | -31.56% | -8.82% | 83.62% | 48.62% |
Operating Margin | -398.40% | -300.47% | -648.24% | -506.25% | 8.05% | -191.75% |
Pretax Margin | -311.63% | -242.38% | -439.79% | -278.04% | -12.37% | -222.27% |
Profit Margin | -306.37% | -238.98% | -433.57% | -256.17% | -22.20% | -222.28% |
FCF Margin | -421.10% | -343.58% | -682.29% | -325.32% | 8.45% | -361.76% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
P/FCF Ratio | - | - | - | - | 71.93 | - |
PS Ratio | 83.06 | 175.37 | 207.68 | 142.43 | 6.08 | 52.60 |